肝癌早期筛查肿瘤标记物研究进展  

Progress in early screening tumor marker of hepatocarcinoma

作　　者：孙建民(综述)[1] 张玉宝(审校)[1] 

机构地区：[1]哈尔滨医科大学附属第三医院肝胆外科,哈尔滨150081

出　　处：《实用肿瘤学杂志》2013年第1期93-96,共4页Practical Oncology Journal

摘　　要：肝癌的早期筛查和术后复发的监测仍是临床工作中的难点，虽然已经有甲胎蛋白、CA19—9、AFU、GGT、人端粒酶反转录酶mRNA、热休克蛋白等肿瘤标记物在临床上广泛应用，但是每种肿瘤标记物都存在一定弊端，特异性不强，往往需要联合检测才能提高诊断的准确性。糖生物学中的异常糖基化被认为与肿瘤的发生发展有密切关系，因此研究异常糖基化成为近年来的研究热点。N-糖链是异常糖基化的一种，检测特异性的N-糖链有望成为筛查及监测肝癌患者变化的动态指标。Early screening and monitoring recurrence of hepatocarcinoma postoperative were still the most challenging works in clinical work, although there were AFP, CA199, AFU, GGT, Human telomerase reverse transcriptase mRNA and heat shock protein as tumor markers in clinical application. But, each tumor marker has some disadvantage. Specificity is not strong, which often needs to unite detection for improving the accuracy of the diagnosis. Abnormal glycosylation of glycobiology has a close relationship with tumor. So, the study of abnormal glycosyl has become hot issue in recently years. N - glycan is a kind of abnormal glycosylation. Thus, the detection of specific N - glycan may become dynamic changing index in screening and monitoring hepatocarcinoma.

关 键 词：肿瘤标记物 肝癌 N-糖链 

分 类 号：R734.3[医药卫生—肿瘤]